Your browser doesn't support javascript.
loading
Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases.
Mansinho, André; Ferreira, Arlindo R; Casimiro, Sandra; Alho, Irina; Vendrell, Inês; Costa, Ana Lúcia; Sousa, Rita; Abreu, Catarina; Pulido, Catarina; Macedo, Daniela; Pacheco, Teresa R; Correia, Lurdes; Costa, Luís.
Afiliación
  • Mansinho A; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. andr3.m@gmail.com.
  • Ferreira AR; Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. andr3.m@gmail.com.
  • Casimiro S; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. ajrsferreira@gmail.com.
  • Alho I; Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. ajrsferreira@gmail.com.
  • Vendrell I; Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. scasimiro@medicina.ulisboa.pt.
  • Costa AL; Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. irina.mpmad@gmail.com.
  • Sousa R; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. inesvendrell@gmail.com.
  • Abreu C; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. c.ana.lucia4@gmail.com.
  • Pulido C; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. arita.sousa@gmail.com.
  • Macedo D; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. catarinaabreupm@hotmail.com.
  • Pacheco TR; Oncology Department, Hospital da Luz, Lisbon, Portugal. pulido.catarina@gmail.com.
  • Correia L; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. danielavgmacedo@hotmail.com.
  • Costa L; Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. tr.pacheco@gmail.com.
Int J Mol Sci ; 20(3)2019 Feb 06.
Article en En | MEDLINE | ID: mdl-30736285
The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors. A cohort of 112 patients with cancer and metastatic bone disease were treated with bone-targeted agents (BTA). Serum baseline FGF23 was quantified by ELISA and dichotomized in FGF23high and FGF23low groups. Additionally, the association between FGF23 and overall survival (OS) and time to skeletal-related events (TTSRE) was investigated. Baseline characteristics were balanced between groups, except for the median urinary N-terminal telopeptide (uNTX) level. After a median follow-up of 26.0 months, a median OS of 34.4 and 12.2 months was found in the FGF23low and FGF23high groups, respectively (multivariate HR 0.18, 95% CI 0.07⁻0.44, p = 0.001; univariate HR 0.27, p = 0.001). Additionally, TTSRE was significantly longer for patients with FGF23low (13.0 vs 2.0 months, p = 0.04). Overall, this study found that patients with FGF23low at baseline had longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and in the use of drugs targeting the FGF axis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Biomarcadores de Tumor / Factores de Crecimiento de Fibroblastos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Biomarcadores de Tumor / Factores de Crecimiento de Fibroblastos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Suiza